期刊
CLINICS IN LIVER DISEASE
卷 22, 期 1, 页码 23-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.cld.2017.08.007
关键词
Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Inflammation; Fibrosis; Genetic factors
资金
- Allergan
- Galectin
- Gilead
- Immuron
- Intercept
- NGM Biopharma
Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver disorders ranging from hepatic steatosis to nonalcoholic steatohepatitis (NASH) and ultimately may lead to cirrhosis. Hepatic steatosis or fatty liver is defined as increased accumulation of lipids in hepatocytes and results from increased production or reduced clearance of hepatic triglycerides or fatty acids. Fatty liver can progress to NASH in a significant proportion of subjects. NASH is a necroinflammatory liver disease governed by multiple pathways that are not completely elucidated. This article describes the main mechanisms that have been reported to contribute to the pathophysiology of NAFLD and NASH.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据